POLE and colorectal carcinoma: In a study of 50 patients with resected stage II/III CRC with POLE mutations, both dMMR and POLE mutant tumors had less likelihood of recurrence, although POLE mutant tumors fared better with an 8% risk of recurrence compared to 18.9% among dMMR tumors and 27.8% among pMMR tumors, independent of RAS or BRAF status [75].